PPCBHealthcare · Biotechnology

PPCB Stock Forecast: Propanc Biopharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.08

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$2.5M

Ticker Nerd rank

41 / 100

Median analyst target

—

Analysts covering

Ticker Nerd rank

PPCB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Propanc Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Quality

Volatility

Revisions

Momentum

Value

Issuance

Size (98): Smaller than most of the companies we track.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PPCB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PPCB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PPCB appears on the weeks it earns a place.

Estimates

PPCB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Propanc Biopharma, Inc. (PPCB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 0.1×
EV / EBITDA: −0.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −127.0%
Return on assets: −62.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PPCB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PPCBPropanc Biopharma, Inc.	$2.5M	41
SPRCSciSparc Ltd.	$3.8M	24
XRTXXORTX Therapeutics, Inc.	$3.8M	15
GRIGRI Bio, Inc.	$3.6M	30
SXTP60 Degrees Pharmaceuticals, Inc.	$4.0M	30
HCWBHCW Biologics Inc.	$4.0M	66
CLDICalidi Biotherapeutics, Inc.	$3.5M	23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Propanc Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PPCB news & analysis

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

GlobeNewsWire · 18 Aug 2026positive

Propanc Biopharma announced it has begun finalizing a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors. Preparatory activities, led by Avance Clinical Pty Ltd, include reviewing the Investigator's Brochure, preparing a Briefing Document, and finalizing the Clinical Trial Protocol.

Why it matters — This marks a step toward the company's first-in-human clinical study of its PRP cancer therapy, a key milestone for PPCB's development pipeline.

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

GlobeNewsWire · 12 Aug 2026positive

Propanc Biopharma highlighted its differentiated proenzyme therapy PRP as a potential therapy of choice against RAS-driven cancers, noting that further improvements can be made through complementary treatment modalities such as PRP that target how cancer cells become malignant, invasive and spread.

Why it matters — PPCB watchers would care because this highlights the company's positioning of PRP as a potential treatment option for RAS-driven cancers, underscoring its pipeline's therapeutic relevance.

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

GlobeNewsWire · 6 Aug 2026positive

Propanc Biopharma announced new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) models. In orthotopic and patient-derived xenograft models, intravenous PRP achieved greater than 90% mean tumor growth inhibition, reduced metastatic burden, remodeled the tumor microenvironment, enhanced chemo-resistant cells' sensitivity to standard-of-care chemotherapy, and extended median overall survival by more than 2.5-fold compared with controls.

Why it matters — The positive preclinical and translational results for PRP represent progress for Propanc's lead candidate in a difficult-to-treat cancer, which may be relevant to investors tracking the company's development pipeline.

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

GlobeNewsWire · 5 Aug 2026positive

Propanc Biopharma announced it is completing the first tranche of $500,000 of its $5.0 million share repurchase program within the first 30 days since the program commenced. The company also noted it is progressing toward a Phase 1b, First-In-Human study in 40–45 advanced cancer patients with solid tumors across trial centers in Australia.

Why it matters — A PPCB watcher would care because the company is actively returning capital to shareholders via its repurchase program while advancing its lead candidate into a First-In-Human Phase 1b study.

FAQ

Frequently asked questions about PPCB stock

How does Ticker Nerd's model rank PPCB?

As at 22 Aug 2026, Propanc Biopharma, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the PPCB stock forecast for 2030?

No analyst covering Propanc Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PPCB are extrapolating price history, which says nothing about the business.

What does Propanc Biopharma, Inc. do?

Propanc Biopharma Inc. is a biopharmaceutical company focused on the development of novel cancer treatments.

What is the latest news on PPCB?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP". Propanc Biopharma announced it has begun finalizing a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors. Preparatory activities, led by Avance Clinical Pty Ltd, include reviewing the Investigator's Brochure, preparing a Briefing Document, and finalizing the Clinical Trial Protocol.

Company

About Propanc Biopharma, Inc.

Propanc Biopharma Inc. is a biopharmaceutical company focused on the development of novel cancer treatments. The primary function of the company is to research and develop therapeutic solutions specifically targeting cancerous tumors. Its innovative approach involves proenzyme therapy, which utilizes proenzymes or inactive precursors of enzymes, as a potential solution to treating a variety of cancer types by targeting and inhibiting cancerous cells. The biotechnology sector recognizes Propanc Biopharma for its pioneering work in advancing methods to prevent tumor recurrence and metastasis. The company's efforts target diseases with high unmet medical needs, aiming to improve patient outcomes with fewer side effects compared to conventional treatment options. Propanc Biopharma plays a significant role in the healthcare and life sciences sectors, contributing to the ongoing evolution of cancer treatment strategies. Operating within a competitive and rapidly advancing industry, Propanc Biopharma is a part of the broader movement towards innovative cancer therapies that redefine treatment paradigms and offer hope to patients worldwide.

CEO Mr. James Nathanielsz · 1 employees · Australia · https://www.propanc.com